Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Cwm LLC

Cwm LLC increased its holdings in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 3.1% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 126,702 shares of the medical research company’s stock after acquiring an additional 3,804 shares during the period. Cwm LLC’s holdings in Amgen were worth $36,024,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of AMGN. BOK Financial Private Wealth Inc. acquired a new stake in Amgen in the 4th quarter worth about $29,000. United Community Bank acquired a new stake in Amgen in the 4th quarter worth about $29,000. Planned Solutions Inc. acquired a new stake in Amgen in the 4th quarter worth about $30,000. Delos Wealth Advisors LLC boosted its holdings in Amgen by 2,500.0% in the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the last quarter. Finally, Providence Capital Advisors LLC acquired a new stake in Amgen in the 3rd quarter worth about $30,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 2,117 shares of the firm’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now owns 9,883 shares of the company’s stock, valued at $3,094,268.47. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on AMGN shares. raised shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. William Blair raised shares of Amgen from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. UBS Group raised their target price on shares of Amgen from $284.00 to $307.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Truist Financial reissued a “buy” rating and issued a $320.00 target price on shares of Amgen in a research note on Friday, April 12th. Finally, Raymond James started coverage on shares of Amgen in a research note on Thursday, March 28th. They issued a “market perform” rating on the stock. Ten research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and a consensus price target of $305.85.

Check Out Our Latest Analysis on Amgen

Amgen Stock Up 0.9 %

NASDAQ:AMGN traded up $2.71 during trading hours on Wednesday, hitting $305.99. The company’s stock had a trading volume of 2,166,202 shares, compared to its average volume of 2,101,200. The stock has a market capitalization of $164.14 billion, a P/E ratio of 43.71, a price-to-earnings-growth ratio of 2.74 and a beta of 0.60. The stock has a fifty day moving average of $294.16 and a 200-day moving average of $290.05. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 52-week low of $218.44 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGNGet Free Report) last posted its earnings results on Thursday, May 2nd. The medical research company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.76 by $0.20. The firm had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.45 billion. Amgen had a return on equity of 156.21% and a net margin of 12.74%. Amgen’s revenue for the quarter was up 22.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.98 earnings per share. On average, equities analysts forecast that Amgen Inc. will post 19.47 earnings per share for the current year.

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.